{"product_id":"gild-porters-five-forces-analysis","title":"Gilead Sciences, Inc. (GILD): 5 FORCES Analysis [June-2026 Updated]","description":"\u003cp\u003eThis ready-made analysis gives you a detailed Michael Porter's Five Forces breakdown of Gilead Sciences, Inc. Business, covering supplier power, customer power, rivalry, substitutes, and entry barriers so you can see what drives pricing, competition, and strategy. It uses key facts such as \u003cstrong\u003e$28.8 billion\u003c\/strong\u003e in 2024 revenue, \u003cstrong\u003e$19.6 billion\u003c\/strong\u003e in HIV sales, \u003cstrong\u003e70.0%\u003c\/strong\u003e U.S. HIV market share for Biktarvy, and the \u003cstrong\u003e$32.0 billion\u003c\/strong\u003e U.S. investment plan through 2030 to help you study the business with real market evidence.\u003c\/p\u003e\u003ch2\u003eGilead Sciences, Inc. - Porter's Five Forces: Bargaining power of suppliers\u003c\/h2\u003e\n\u003cp\u003eSupplier power is low to moderate for Gilead Sciences, Inc. The company's scale, cash generation, and move toward internal ownership of research, manufacturing, and intellectual property reduce the leverage of contract manufacturers, research vendors, and royalty holders.\u003c\/p\u003e\n\n\u003cp\u003eGilead Sciences, Inc. is not a small buyer that has to accept vendor terms. Its \u003cstrong\u003e$32.0 billion\u003c\/strong\u003e U.S. investment plan through 2030, the \u003cstrong\u003e182,000\u003c\/strong\u003e sq ft AI-enabled technical development center in Foster City, and a global workforce of more than \u003cstrong\u003e17,000\u003c\/strong\u003e employees at 2025-12-31 show a broad internal operating base. That matters because a company that can build, staff, and finance its own capacity is less exposed to a narrow supplier group. Year-end 2024 cash, cash equivalents, and marketable debt securities of \u003cstrong\u003e$10.0 billion\u003c\/strong\u003e, plus the \u003cstrong\u003e$3.5 billion\u003c\/strong\u003e senior unsecured notes issued in 2024-Q4, give Gilead Sciences, Inc. room to fund specialized inputs without depending on a few critical vendors.\u003c\/p\u003e\n\n\u003ctable\u003e\n\u003ctr\u003e\n\u003cth\u003eSupplier power driver\u003c\/th\u003e\n\u003cth\u003eWhat the data shows\u003c\/th\u003e\n\u003cth\u003eEffect on Gilead Sciences, Inc.\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eScale\u003c\/td\u003e\n\u003ctd\u003e2024 revenue of \u003cstrong\u003e$28.8 billion\u003c\/strong\u003e, Q4 2024 revenue of \u003cstrong\u003e$7.6 billion\u003c\/strong\u003e, and 2025 product-sales guidance of \u003cstrong\u003e$28.2 billion\u003c\/strong\u003e to \u003cstrong\u003e$28.6 billion\u003c\/strong\u003e\n\u003c\/td\u003e\n \u003ctd\u003eLarge purchasing volume weakens vendor pricing power\u003c\/td\u003e\n \u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eInternal capacity\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e17,000+\u003c\/strong\u003e employees and a \u003cstrong\u003e182,000\u003c\/strong\u003e sq ft technical development center\u003c\/td\u003e\n \u003ctd\u003eMore work can be done in-house, so fewer critical tasks sit with outside suppliers\u003c\/td\u003e\n \u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eLiquidity\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e$10.0 billion\u003c\/strong\u003e in year-end 2024 cash and marketable debt securities, plus \u003cstrong\u003e$3.5 billion\u003c\/strong\u003e of notes issued in 2024-Q4\u003c\/td\u003e\n \u003ctd\u003eGilead Sciences, Inc. can pay for scarce inputs and avoid supplier bottlenecks\u003c\/td\u003e\n \u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOwnership of assets\u003c\/td\u003e\n\u003ctd\u003eCymaBay acquired for \u003cstrong\u003e$4.3 billion\u003c\/strong\u003e in 2024 and a \u003cstrong\u003e$320 million\u003c\/strong\u003e royalty buyout in 2024\u003c\/td\u003e\n \u003ctd\u003eBuying assets outright reduces ongoing royalty dependence\u003c\/td\u003e\n \u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOperational utilities\u003c\/td\u003e\n\u003ctd\u003eFoster City reported \u003cstrong\u003e100%\u003c\/strong\u003e renewable electricity and zero-waste-to-landfill status at 2025-12-31\u003c\/td\u003e\n \u003ctd\u003eUtilities are less likely to become a source of supplier pressure\u003c\/td\u003e\n \u003c\/tr\u003e\n\u003c\/table\u003e\n\n\u003cp\u003eThe strongest reason supplier power stays contained is internalization. Gilead Sciences, Inc. has been willing to buy assets instead of paying recurring tolls. The \u003cstrong\u003e$4.3 billion\u003c\/strong\u003e CymaBay acquisition and the \u003cstrong\u003e$320 million\u003c\/strong\u003e royalty buyout reduced exposure to third-party owners of key commercial rights. That pattern matters in a Porter analysis because supplier power rises when a company must keep paying for access to a critical input. When Company Name owns the asset, controls the license, or builds the capability itself, the supplier's ability to raise prices or tighten terms falls.\u003c\/p\u003e\n\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eLarge revenue base gives Gilead Sciences, Inc. bargaining scale with contract manufacturers and lab service providers.\u003c\/li\u003e\n \u003cli\u003eStrong liquidity lowers the chance that vendors can force unfavorable payment terms.\u003c\/li\u003e\n \u003cli\u003eAcquisitions and royalty buyouts reduce recurring external claims on product economics.\u003c\/li\u003e\n \u003cli\u003eInternal R\u0026amp;D and manufacturing investment reduce dependence on third-party execution.\u003c\/li\u003e\n \u003cli\u003eMulti-therapy diversification across virology, oncology, and inflammation limits any one supplier from becoming indispensable.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003eR\u0026amp;D inputs are also diversified. The 2025 collaboration with Genesis Therapeutics spreads drug-discovery work across an AI platform rather than a single vendor, and the start of the \u003cstrong\u003e182,000\u003c\/strong\u003e sq ft technical development center adds more internal capacity. Full-year 2024 revenue of \u003cstrong\u003e$28.8 billion\u003c\/strong\u003e and Q4 2024 revenue of \u003cstrong\u003e$7.6 billion\u003c\/strong\u003e give Gilead Sciences, Inc. recurring funding for specialized lab services, data tools, and technical support. Because the company's spend is spread across multiple therapeutic areas, no single supplier appears able to dictate terms across the business.\u003c\/p\u003e\n\n\u003cp\u003eCapital access also weakens vendor leverage. A buyer with a year-end 2024 cash position of \u003cstrong\u003e$10.0 billion\u003c\/strong\u003e and \u003cstrong\u003e$3.5 billion\u003c\/strong\u003e of fresh debt financing can commit to procurement and development without relying on supplier financing. The 2024-Q3 dividend of \u003cstrong\u003e$983.0 million\u003c\/strong\u003e and the \u003cstrong\u003e$350 million\u003c\/strong\u003e share repurchase in 2024-Q4 show that cash generation remained strong even after capital returns. That is important because suppliers usually gain power when a buyer is cash constrained and must accept tighter terms. Here, the recurring earnings base from HIV sales of \u003cstrong\u003e$19.6 billion\u003c\/strong\u003e and Biktarvy sales of \u003cstrong\u003e$13.4 billion\u003c\/strong\u003e supports steady demand and gives Gilead Sciences, Inc. room to negotiate.\u003c\/p\u003e\n\n\u003cp\u003eRegulatory and intellectual property control matter just as much as financial scale. The 2025-01-15 PrEP patent settlement with the U.S. DOJ and HHS, along with licenses for future PrEP patents, reduced the risk that outside IP holders could block access to key product rights. The 2025-04-29 civil fraud settlement of \u003cstrong\u003e$202.0 million\u003c\/strong\u003e also removes part of the compliance overhang that can raise risk premiums for partners and vendors. With voluntary HIV licensing in over \u003cstrong\u003e120\u003c\/strong\u003e countries at 2025-12-31, Gilead Sciences, Inc. has already negotiated a broad rights structure rather than depend on a few restrictive licensors. That lowers supplier power because the most important inputs are increasingly owned, financed, or contractually controlled by Company Name.\u003c\/p\u003e\u003ch2\u003eGilead Sciences, Inc. - Porter's Five Forces: Bargaining power of customers\u003c\/h2\u003e\n\u003cp\u003eCustomer power is moderate to high for Gilead Sciences, Inc. because a large share of demand runs through a small number of payers, hospital systems, and government buyers. When a company depends on concentrated franchises such as HIV, buyers can compare prices, demand rebates, and push hard on formulary access.\u003c\/p\u003e\n\n\u003ctable\u003e\n\u003ctr\u003e\n\u003ctd\u003e\u003cstrong\u003eCustomer power driver\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003eData point\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003eWhy it matters\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e2024 revenue base\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$28.8 billion\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eLarge buyers matter because even small pricing changes can move total revenue.\u003c\/td\u003e\n \u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eHIV franchise size\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$19.6 billion\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eOne franchise accounts for most sales, so payers can focus negotiation pressure there.\u003c\/td\u003e\n \u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eBiktarvy sales\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$13.4 billion\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eA dominant product gives buyers a clear benchmark for rebates and access terms.\u003c\/td\u003e\n \u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eU.S. HIV share\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e70.0%\u003c\/strong\u003e on 2024-09-30\u003c\/td\u003e\n\u003ctd\u003eHigh share improves scale, but it also gives buyers a visible standard of care to compare against.\u003c\/td\u003e\n \u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eQ3 2024 revenue\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$7.5 billion\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eQuarterly results depend on reimbursement and formulary decisions.\u003c\/td\u003e\n \u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eQ4 2024 revenue\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$7.6 billion\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eShows that buyer behavior still affects near-term sales momentum.\u003c\/td\u003e\n \u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eLivdelzi launch price\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e$12,606\u003c\/strong\u003e per 30-day supply\u003c\/td\u003e\n \u003ctd\u003eHigh list pricing increases payer scrutiny and rebate pressure.\u003c\/td\u003e\n \u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e2025 product sales guidance\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$28.2 billion to $28.6 billion\u003c\/strong\u003e\u003c\/td\u003e\n \u003ctd\u003eLimited growth room makes concessions more important to buyers.\u003c\/td\u003e\n \u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePrEP settlement\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e2025-01-15\u003c\/strong\u003e DOJ and HHS settlement\u003c\/td\u003e\n \u003ctd\u003eGovernment and public-sector buyers can force economic and legal concessions.\u003c\/td\u003e\n \u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCivil fraud settlement\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e$202 million\u003c\/strong\u003e on 2025-04-29\u003c\/td\u003e\n \u003ctd\u003eShows that public scrutiny can create direct financial costs.\u003c\/td\u003e\n \u003c\/tr\u003e\n\u003c\/table\u003e\n\n\u003cp\u003e\u003cstrong\u003ePayer pressure shows up in pricing\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eGilead Sciences, Inc. lives with heavy payer scrutiny because its biggest products sit in markets where insurers, pharmacy benefit managers, and government programs can compare treatment cost against alternatives. In 2024, total revenue was \u003cstrong\u003e$28.8 billion\u003c\/strong\u003e, HIV sales were \u003cstrong\u003e$19.6 billion\u003c\/strong\u003e, and Biktarvy alone generated \u003cstrong\u003e$13.4 billion\u003c\/strong\u003e. That kind of concentration gives buyers real negotiating leverage because they know where the company is most dependent.\u003c\/p\u003e\n\n\u003cp\u003eBiktarvy still held \u003cstrong\u003e70.0%\u003c\/strong\u003e of the U.S. HIV market on 2024-09-30, which means customers do not need to guess what the standard treatment looks like. They can benchmark against a dominant product and demand lower net pricing, stronger formulary placement, or bigger rebates. Livdelzi launched at \u003cstrong\u003e$12,606\u003c\/strong\u003e per 30-day supply, and that price level almost invites payer review in liver disease. The fact that Gilead Sciences, Inc. guided 2025 product sales to only \u003cstrong\u003e$28.2 billion to $28.6 billion\u003c\/strong\u003e shows how little room there is for pricing mistakes.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eGlobal buyers can negotiate\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eBuyer power rises when the customer base is broad, public, and price sensitive. Gilead Sciences, Inc. maintained voluntary licensing agreements for HIV medication access in more than \u003cstrong\u003e120 countries\u003c\/strong\u003e at 2025-12-31, which increases the number of public purchasers and non-U.S. buyers that can push on access terms. These buyers often care as much about affordability and supply reliability as they do about brand strength.\u003c\/p\u003e\n\n\u003cp\u003eThe company also had over \u003cstrong\u003e17,000\u003c\/strong\u003e employees globally and \u003cstrong\u003e100%\u003c\/strong\u003e renewable electricity across operations at 2025-12-31, so large institutional buyers can compare its operating profile with peers when awarding contracts. Oncology sales were approximately \u003cstrong\u003e12.0%\u003c\/strong\u003e of total revenue at 2025-12-31, up from \u003cstrong\u003e$3.3 billion\u003c\/strong\u003e in 2024, which means specialty oncology buyers are less tied to any single product. Veklury produced about \u003cstrong\u003e$1.8 billion\u003c\/strong\u003e of full-year 2024 revenue, but hospital and government buyers in that category can shift quickly if another therapy becomes preferred.\u003c\/p\u003e\n\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eManaged care plans can demand lower net prices through rebates.\u003c\/li\u003e\n \u003cli\u003eHospitals can switch procurement based on clinical guidelines and reimbursement.\u003c\/li\u003e\n \u003cli\u003eGovernment buyers can press for access, discounts, and legal remedies.\u003c\/li\u003e\n \u003cli\u003eInternational buyers can use licensing terms to reduce cost.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\u003cstrong\u003eFranchise concentration weakens pricing\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eWhen one franchise drives most revenue, buyers gain leverage because they know where price pressure will hurt most. HIV sales reached \u003cstrong\u003e$19.6 billion\u003c\/strong\u003e in 2024, and Biktarvy's \u003cstrong\u003e$13.4 billion\u003c\/strong\u003e of sales made it the clear anchor product. That matters because the buyer can point to a visible standard of care and ask for a better deal, especially when the product already dominates the market.\u003c\/p\u003e\n\n\u003cp\u003eGilead Sciences, Inc. had \u003cstrong\u003e$28.8 billion\u003c\/strong\u003e in total revenue in 2024 and guided to just \u003cstrong\u003e$28.2 billion to $28.6 billion\u003c\/strong\u003e in 2025 product sales. That modest growth range means any rebate increase, formulary loss, or slower reimbursement can matter more. Livdelzi's \u003cstrong\u003e$12,606\u003c\/strong\u003e monthly launch price also raises affordability questions in a market where the company had already paid \u003cstrong\u003e$4.3 billion\u003c\/strong\u003e to secure the asset. When buyers can compare a dominant HIV franchise, a newer liver therapy, and a \u003cstrong\u003e$1.8 billion\u003c\/strong\u003e COVID treatment, they are in a stronger position to negotiate economics.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eLitigation strengthens buyer voice\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThe 2025-01-15 settlement with DOJ and HHS on PrEP patents and the 2025-04-29 \u003cstrong\u003e$202 million\u003c\/strong\u003e civil fraud settlement show that government pressure can turn into direct economic cost. That matters because the pressure arrived after a 2024 revenue base of \u003cstrong\u003e$28.8 billion\u003c\/strong\u003e, so public scrutiny can still affect a company that has a large sales base. For customers, settlements signal that pricing, access, and patent terms are negotiable under legal pressure.\u003c\/p\u003e\n\n\u003cp\u003eGilead Sciences, Inc. booked \u003cstrong\u003e$7.5 billion\u003c\/strong\u003e of revenue in Q3 2024 and \u003cstrong\u003e$7.6 billion\u003c\/strong\u003e in Q4 2024, which shows that quarterly sales still depend on reimbursement timing and buying decisions. The settlement also secured licenses for future PrEP patents, which gives purchasers more room to challenge future pricing in prevention. In a business where HIV alone delivered \u003cstrong\u003e$19.6 billion\u003c\/strong\u003e and Biktarvy delivered \u003cstrong\u003e$13.4 billion\u003c\/strong\u003e, even small discounts can become large dollar amounts quickly.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eAccess programs shape demand\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eAccess programs expand the number of price-sensitive buyers. Gilead Sciences, Inc. used voluntary HIV licensing in more than \u003cstrong\u003e120 countries\u003c\/strong\u003e at 2025-12-31, which broadens access but also increases the number of public and low-income buyers that expect lower prices. That access footprint sits beside a 2024 business that generated \u003cstrong\u003e$28.8 billion\u003c\/strong\u003e in revenue and a 2025 sales outlook of \u003cstrong\u003e$28.2 billion to $28.6 billion\u003c\/strong\u003e.\u003c\/p\u003e\n\n\u003cp\u003eThe company's oncology mix of about \u003cstrong\u003e12.0%\u003c\/strong\u003e of total revenue at 2025-12-31 means it has to answer to hospital systems, oncology clinics, and payers beyond the HIV base. Livdelzi's \u003cstrong\u003e$12,606\u003c\/strong\u003e launch price and the \u003cstrong\u003e$1.75 billion\u003c\/strong\u003e Trodelvy-related impairment in Q3 2024 both show that customers are already testing pricing outcomes. Because Gilead Sciences, Inc. sells across HIV, oncology, liver disease, and COVID treatment, buyers in each channel can compare its offers against other therapies and ask for better economics.\u003c\/p\u003e\n\u003ch2\u003eGilead Sciences, Inc. - Porter's Five Forces: Competitive rivalry\u003c\/h2\u003e\n\u003cp\u003eCompetitive rivalry is high for Gilead Sciences, Inc. because the company competes in large, crowded therapeutic areas where rivals can win share through better efficacy, simpler dosing, or stronger payer access. The pressure is not only from outside competitors; it also comes from Gilead Sciences, Inc. launching products that can replace older ones inside its own portfolio.\u003c\/p\u003e\n\n\u003cp\u003eThe HIV franchise shows this most clearly. Biktarvy held \u003cstrong\u003e70.0%\u003c\/strong\u003e of the U.S. HIV market on 2024-09-30 and still generated \u003cstrong\u003e$13.4 billion\u003c\/strong\u003e in 2024 sales, but Gilead Sciences, Inc. also advanced a BIC\/LEN oral combination that met primary endpoints in two Phase 3 studies and achieved non-inferiority to Biktarvy on 2025-12-15. Yeztugo, the long-acting lenacapavir prevention brand, launched on 2026-02-25 after PURPOSE 2 showed superior efficacy and the FDA granted Breakthrough Therapy Designation on 2024-11-06. That means rivalry is partly self-inflicted: Gilead Sciences, Inc. must defend a large incumbent product while shifting patients toward a newer option that can change adherence patterns, dosing frequency, and payer negotiations.\u003c\/p\u003e\n\n\u003ctable\u003e\n\u003ctr\u003e\n\u003cth\u003eCompetitive area\u003c\/th\u003e\n\u003cth\u003eMain rival pressure\u003c\/th\u003e\n\u003cth\u003eEvidence of rivalry\u003c\/th\u003e\n\u003cth\u003eWhy it matters for Gilead Sciences, Inc.\u003c\/th\u003e\n \u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eHIV treatment and prevention\u003c\/td\u003e\n\u003ctd\u003eFast followers, longer-acting products, and oral combinations\u003c\/td\u003e\n \u003ctd\u003eBiktarvy held \u003cstrong\u003e70.0%\u003c\/strong\u003e U.S. share on 2024-09-30; BIC\/LEN was non-inferior on 2025-12-15; Yeztugo launched on 2026-02-25\u003c\/td\u003e\n \u003ctd\u003ePatient switching, physician preference, and payer control can shift revenue quickly in a franchise that produced \u003cstrong\u003e$19.6 billion\u003c\/strong\u003e of HIV sales in 2024\u003c\/td\u003e\n \u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOncology\u003c\/td\u003e\n\u003ctd\u003eApproved antibody-drug conjugates and combo regimens\u003c\/td\u003e\n \u003ctd\u003eTrodelvy faced pressure from Enhertu and Datroway; ASCENT-04 showed progression-free survival of \u003cstrong\u003e11.2 months\u003c\/strong\u003e versus \u003cstrong\u003e7.8 months\u003c\/strong\u003e for chemotherapy\u003c\/td\u003e\n \u003ctd\u003eEven positive trial data must compete against multiple approved options in the same tumor types\u003c\/td\u003e\n \u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eLiver and inflammation\u003c\/td\u003e\n\u003ctd\u003eEstablished incumbents and future entrants\u003c\/td\u003e\n \u003ctd\u003eLivdelzi received accelerated approval on 2024-08-14 and remained tied to confirmatory survival-benefit data\u003c\/td\u003e\n \u003ctd\u003eApproval alone does not secure share; evidence generation still decides whether the product lasts\u003c\/td\u003e\n \u003c\/tr\u003e\n\u003c\/table\u003e\n\n\u003cp\u003eOncology is a direct rivalry test. Trodelvy faced competitive pressure in HER2-low breast cancer from AstraZeneca and Daiichi Sankyo's Enhertu on 2024-06-01, and Datroway became the first FDA-approved TROP2 ADC for EGFR-mutated NSCLC on 2025-06-01. Gilead Sciences, Inc. still reported that ASCENT-04 showed Trodelvy plus Keytruda improved progression-free survival to \u003cstrong\u003e11.2 months\u003c\/strong\u003e versus \u003cstrong\u003e7.8 months\u003c\/strong\u003e for chemotherapy, but that result has to fight for uptake against multiple approved regimens. The company also recorded a \u003cstrong\u003e$1.75 billion\u003c\/strong\u003e Trodelvy-related impairment in Q3 2024, which is a strong signal that commercial expectations were reset by rival data and market adoption.\u003c\/p\u003e\n\n\u003cul\u003e\n\u003cli\u003eRival products in oncology are not just competing on price; they are competing on clinical endpoints, label strength, and ease of use.\u003c\/li\u003e\n \u003cli\u003eTrodelvy's pressure matters because oncology revenue reached \u003cstrong\u003e$3.3 billion\u003c\/strong\u003e in 2024 and about \u003cstrong\u003e12.0%\u003c\/strong\u003e of total revenue by 2025-12-31.\u003c\/li\u003e\n \u003cli\u003eWhen a drug class has several approved alternatives, physicians can switch faster if one product shows clearer benefit or fewer side effects.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003eDiversification does not remove rivalry. Gilead Sciences, Inc. reported \u003cstrong\u003e$7.6 billion\u003c\/strong\u003e of revenue in Q4 2024, up \u003cstrong\u003e6.0%\u003c\/strong\u003e year over year, and \u003cstrong\u003e$7.5 billion\u003c\/strong\u003e in Q3 2024, up \u003cstrong\u003e7.0%\u003c\/strong\u003e, but those growth rates still point to moderate expansion in markets where competitors keep launching new therapies. Full-year 2024 revenue reached \u003cstrong\u003e$28.8 billion\u003c\/strong\u003e, and 2025 total product sales guidance of \u003cstrong\u003e$28.2 billion\u003c\/strong\u003e to \u003cstrong\u003e$28.6 billion\u003c\/strong\u003e shows management still sees a tight competitive range. The issuance of \u003cstrong\u003e$3.5 billion\u003c\/strong\u003e in senior unsecured notes in 2024-Q4 and the \u003cstrong\u003e$10.0 billion\u003c\/strong\u003e of cash and marketable debt securities at 2024-12-31 show how much capital is needed to stay competitive across research, launches, and business development.\u003c\/p\u003e\n\n\u003cp\u003eThe rivalry also shows up in leadership and infrastructure choices. The CMO transition from Merdad Parsey to Dietmar Berger after the 2024-07-17 announcement reflects the need to keep pace across virology, oncology, and inflammation. The 2025-09-05 Foster City AI-enabled development center and the \u003cstrong\u003e$32.0 billion\u003c\/strong\u003e capital plan through 2030 are responses to a market where development speed and differentiation matter as much as scale. In academic terms, this is a useful example of how internal capabilities can become a response to external rivalry.\u003c\/p\u003e\n\n\u003cp\u003eIn liver and inflammation, Gilead Sciences, Inc. is entering newer areas where rivals still have room to challenge share. Livdelzi launched at \u003cstrong\u003e$12,606\u003c\/strong\u003e per 30-day supply and remained contingent on confirmatory Phase 3 survival-benefit data, so the competitive position still depends on evidence generation rather than approval alone. The company's 2025-12-31 oncology sales mix of about \u003cstrong\u003e12.0%\u003c\/strong\u003e of total revenue also shows that Gilead Sciences, Inc. is still trying to rebalance away from HIV concentration, which keeps rivalry active across multiple therapeutic categories at once.\u003c\/p\u003e\n\n\u003cul\u003e\n\u003cli\u003eHigh share can attract more direct attacks from rivals.\u003c\/li\u003e\n \u003cli\u003eInternal replacement products can protect the franchise, but they can also cannibalize older sales.\u003c\/li\u003e\n \u003cli\u003eClinical trial wins matter only if they convert into prescribing, reimbursement, and durable market share.\u003c\/li\u003e\n \u003cli\u003eCapital spending, debt issuance, and leadership changes are signs that rivalry is shaping strategy, not just sales.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003eMarket share makes Gilead Sciences, Inc. a target. A \u003cstrong\u003e70.0%\u003c\/strong\u003e U.S. HIV share for Biktarvy and \u003cstrong\u003e$13.4 billion\u003c\/strong\u003e in product sales put a large, visible asset in front of rivals, while \u003cstrong\u003e$19.6 billion\u003c\/strong\u003e of HIV sales in 2024 and \u003cstrong\u003e$28.8 billion\u003c\/strong\u003e of total revenue show how quickly group results can move if the franchise weakens. The launch of Yeztugo and the non-inferiority result for BIC\/LEN show that Gilead Sciences, Inc. itself is supplying the next round of competitive options. That keeps rivalry intense because the company must defend today's revenue while replacing it with tomorrow's products.\u003c\/p\u003e\u003ch2\u003eGilead Sciences, Inc. - Porter's Five Forces: Threat of substitutes\u003c\/h2\u003e\n\u003cp\u003eThe threat of substitutes is high for Gilead Sciences, Inc. because patients, clinicians, hospitals, and payers can switch to different dose forms, different mechanisms, or different access models that solve the same medical problem. That matters because Gilead still depends on large franchises such as \u003cstrong\u003e$19.6 billion\u003c\/strong\u003e in HIV sales in 2024 and a \u003cstrong\u003e$13.4 billion\u003c\/strong\u003e Biktarvy franchise, so even small substitution shifts can move meaningful revenue.\u003c\/p\u003e\n\n\u003cp\u003eA substitute is another product or treatment that delivers a similar outcome in a different way. In Gilead Sciences, Inc., the strongest substitute pressure comes from convenience changes in HIV prevention, older chemotherapy and rival oncology drugs, and access alternatives that make branded products easier to replace.\u003c\/p\u003e\n\n\u003ctable\u003e\n\u003ctr\u003e\n\u003ctd\u003e\u003cstrong\u003eSubstitute pressure\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003eWhat it can replace\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003eWhy it matters\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003eGilead Sciences, Inc. signal\u003c\/strong\u003e\u003c\/td\u003e\n \u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eLong-acting HIV prevention\u003c\/td\u003e\n\u003ctd\u003eDaily oral prevention regimens\u003c\/td\u003e\n\u003ctd\u003eConvenience becomes a direct buying criterion when dosing moves from daily tablets to long-acting injections\u003c\/td\u003e\n \u003ctd\u003eYeztugo launched on 2026-02-25; PURPOSE 2 showed superior efficacy for lenacapavir; FDA Breakthrough Therapy Designation came on 2024-11-06\u003c\/td\u003e\n \u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eInternal HIV portfolio replacement\u003c\/td\u003e\n\u003ctd\u003eBiktarvy and older HIV combinations\u003c\/td\u003e\n\u003ctd\u003eGilead Sciences, Inc. can cannibalize its own cash cows if newer regimens win on dosing or tolerability\u003c\/td\u003e\n \u003ctd\u003eBIC\/LEN met primary endpoints in two Phase 3 studies and was non-inferior to Biktarvy on 2025-12-15; Biktarvy held 70.0% of the U.S. HIV market\u003c\/td\u003e\n \u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOlder cancer regimens and rival oncology drugs\u003c\/td\u003e\n \u003ctd\u003eFirst-line chemotherapy and competing targeted therapies\u003c\/td\u003e\n \u003ctd\u003eOncology choices shift fast when a rival drug offers better progression-free survival or a better biomarker fit\u003c\/td\u003e\n \u003ctd\u003eASCENT-04 showed 11.2 months PFS versus 7.8 months for chemotherapy; Enhertu and Datroway also pressure switching\u003c\/td\u003e\n \u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAccess and licensing models\u003c\/td\u003e\n\u003ctd\u003eBranded pricing and closed-market sales\u003c\/td\u003e\n\u003ctd\u003eLower-cost channels reduce the need to buy premium-priced branded products\u003c\/td\u003e\n \u003ctd\u003eVoluntary HIV licensing covered more than 120 countries at 2025-12-31; Livdelzi launched at \u003cstrong\u003e$12,606\u003c\/strong\u003e per 30-day supply on 2024-08-14\u003c\/td\u003e\n \u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eHospital formulary and protocol changes\u003c\/td\u003e\n\u003ctd\u003eHospital antiviral and supportive-care use\u003c\/td\u003e\n \u003ctd\u003eProtocols can shift demand away from a single branded product even without a direct clinical failure\u003c\/td\u003e\n \u003ctd\u003eVeklury generated about \u003cstrong\u003e$1.8 billion\u003c\/strong\u003e in 2024 revenue, but formulary choices can still favor rival antivirals or supportive care\u003c\/td\u003e\n \u003c\/tr\u003e\n\u003c\/table\u003e\n\n\u003cp\u003eIn HIV prevention, the substitution risk is not just another pill. Yeztugo gives prescribers a long-acting option, while Gilead Sciences, Inc. also showed that BIC\/LEN can compete with Biktarvy on a once-daily basis. That means convenience is now a competitive variable, not a side issue. PURPOSE 2 already showed superior efficacy for lenacapavir in HIV prevention, and the FDA's Breakthrough Therapy Designation on 2024-11-06 strengthens the case for switching away from older prevention approaches. With Biktarvy still holding \u003cstrong\u003e70.0%\u003c\/strong\u003e of the U.S. HIV market, substitution can happen inside the company's own portfolio, which is usually less visible than external competition but just as damaging to future revenue.\u003c\/p\u003e\n\n\u003cp\u003eIn oncology, substitutes remain broad because treatment selection changes with tumor biology, line of therapy, and payer rules. Trodelvy plus Keytruda improved progression-free survival to \u003cstrong\u003e11.2 months\u003c\/strong\u003e versus \u003cstrong\u003e7.8 months\u003c\/strong\u003e for chemotherapy in ASCENT-04, but the chemotherapy arm shows that older regimens still stay in play when doctors compare risk, cost, and patient condition. Gilead Sciences, Inc. also faces substitution from Enhertu in HER2-low breast cancer and Datroway in EGFR-mutated NSCLC. That matters because oncology sales were \u003cstrong\u003e$3.3 billion\u003c\/strong\u003e in 2024 and about \u003cstrong\u003e12.0%\u003c\/strong\u003e of total revenue by 2025-12-31, so switching in one indication can affect a meaningful share of earnings. The \u003cstrong\u003e$1.75 billion\u003c\/strong\u003e Trodelvy-related impairment in Q3 2024 shows that the market already discounted part of the asset's future cash flow.\u003c\/p\u003e\n\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eConvenience can replace efficacy as the first decision filter in HIV prevention when dosing changes from daily to long-acting.\u003c\/li\u003e\n \u003cli\u003eBiomarker-driven oncology creates multiple substitute paths, because one patient may move to chemotherapy while another moves to a targeted drug.\u003c\/li\u003e\n \u003cli\u003eAccess channels can substitute for premium pricing when voluntary licenses expand lower-cost supply across more than 120 countries.\u003c\/li\u003e\n \u003cli\u003eInternal replacement is a real threat when next-generation products can take share from legacy products before the old products fully mature.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003eAccess and pricing also raise substitute pressure because buyers often compare branded products with lower-cost or easier-access alternatives. Gilead Sciences, Inc. maintained voluntary licensing agreements for HIV medication access in more than 120 countries at 2025-12-31, which widens the number of settings where a branded product can be replaced by a cheaper channel. Livdelzi entered at \u003cstrong\u003e$12,606\u003c\/strong\u003e per 30-day supply after accelerated approval on 2024-08-14, but the approval was conditional on confirmatory Phase 3 trials that still need to verify survival benefit in compensated liver cirrhosis. That leaves room for alternative therapies, payer restrictions, or access-driven switching before the product becomes fully established. The company's \u003cstrong\u003e$202 million\u003c\/strong\u003e civil settlement over HIV speaker programs also shows that non-clinical issues can push customers and institutions toward alternative options.\u003c\/p\u003e\n\n\u003cp\u003eGilead Sciences, Inc. is trying to answer substitute pressure with its own pipeline and capital spending. The company plans \u003cstrong\u003e$32.0 billion\u003c\/strong\u003e through 2030 in U.S. research and manufacturing, which is a direct bet that better products will replace weaker ones before rivals do. That strategy matters because total revenue was \u003cstrong\u003e$28.8 billion\u003c\/strong\u003e in 2024, while 2025 product-sales guidance was \u003cstrong\u003e$28.2 billion\u003c\/strong\u003e to \u003cstrong\u003e$28.6 billion\u003c\/strong\u003e. Those numbers show how much value is tied to continued adoption of the preferred therapies rather than to the market as a whole. In Porter's terms, the substitute threat is not only external rivalry; it is also the risk that Gilead Sciences, Inc. replaces its own older cash generators with newer, more convenient, or more effective treatments.\u003c\/p\u003e\u003ch2\u003eGilead Sciences, Inc. - Porter's Five Forces: Threat of new entrants\u003c\/h2\u003e\n\u003cp\u003eThe threat of new entrants is low. Gilead Sciences, Inc. combines high capital needs, strict regulation, strong brand access, and a deep pipeline, so a new biopharma company would need years of funding and proof before it could compete at meaningful scale.\u003c\/p\u003e\n\n\u003cp\u003eCapital is the first barrier. Gilead Sciences, Inc. has a \u003cstrong\u003e$32.0 billion\u003c\/strong\u003e U.S. investment plan through 2030, a \u003cstrong\u003e182,000 sq ft\u003c\/strong\u003e AI-enabled technical development center in Foster City, and more than \u003cstrong\u003e17,000\u003c\/strong\u003e global employees. That scale gap matters because a new entrant would need to build research, manufacturing, regulatory, and commercial capability at the same time. Gilead Sciences, Inc. also had \u003cstrong\u003e$10.0 billion\u003c\/strong\u003e in cash, cash equivalents, and marketable debt securities at 2024-12-31 and issued \u003cstrong\u003e$3.5 billion\u003c\/strong\u003e in senior unsecured notes in 2024-Q4. In plain English, it can fund long drug-development cycles without immediate outside dependence. Its 2024 revenue of \u003cstrong\u003e$28.8 billion\u003c\/strong\u003e, HIV sales of \u003cstrong\u003e$19.6 billion\u003c\/strong\u003e, and Biktarvy sales of \u003cstrong\u003e$13.4 billion\u003c\/strong\u003e show a commercial base that a new firm cannot quickly copy.\u003c\/p\u003e\n\n\u003ctable\u003e\n\u003ctr\u003e\n\u003cth\u003eBarrier\u003c\/th\u003e\n\u003cth\u003eGilead Sciences, Inc. evidence\u003c\/th\u003e\n\u003cth\u003eWhy it blocks new entrants\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCapital scale\u003c\/td\u003e\n\u003ctd\u003e$32.0 billion U.S. investment plan through 2030; $10.0 billion liquidity at 2024-12-31; $3.5 billion notes issued in 2024-Q4\u003c\/td\u003e\n \u003ctd\u003eNew firms need large, patient funding before they can build labs, trials, and commercial infrastructure\u003c\/td\u003e\n \u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCommercial reach\u003c\/td\u003e\n\u003ctd\u003e$28.8 billion in 2024 revenue; $19.6 billion HIV sales; $13.4 billion Biktarvy sales\u003c\/td\u003e\n \u003ctd\u003eEntrants must match payer access, distribution, and physician trust to win prescriptions\u003c\/td\u003e\n \u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTherapeutic breadth\u003c\/td\u003e\n\u003ctd\u003eOncology sales of $3.3 billion and about 12.0% of total revenue by 2025-12-31\u003c\/td\u003e\n \u003ctd\u003eMultiple franchises reduce dependence on one product and raise the scale needed to compete\u003c\/td\u003e\n \u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRegulatory burden\u003c\/td\u003e\n\u003ctd\u003eLivdelzi accelerated FDA approval on 2024-08-14 with confirmatory Phase 3 requirements\u003c\/td\u003e\n \u003ctd\u003eEven approved drugs still need proof, follow-up trials, and regulatory discipline\u003c\/td\u003e\n \u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eLegal and access complexity\u003c\/td\u003e\n\u003ctd\u003eFive-year PrEP litigation resolved on 2025-01-15; civil fraud settlement of $202.0 million on 2025-04-29; voluntary HIV licensing in over 120 countries at 2025-12-31\u003c\/td\u003e\n \u003ctd\u003eEntrants face patents, licensing, compliance, and access terms that are hard to negotiate quickly\u003c\/td\u003e\n \u003c\/tr\u003e\n\u003c\/table\u003e\n\n\u003cp\u003eRegulation creates a second barrier. Livdelzi received accelerated FDA approval on 2024-08-14 only after Gilead Sciences, Inc. accepted a confirmatory Phase 3 requirement to verify survival benefit in compensated liver cirrhosis. That matters because approval is not the end of the process; it often starts the next layer of testing and oversight. Gilead Sciences, Inc. also resolved five-year PrEP litigation with the U.S. DOJ and HHS on 2025-01-15 and secured licenses for future PrEP patents, then settled a civil fraud lawsuit for \u003cstrong\u003e$202.0 million\u003c\/strong\u003e on 2025-04-29. These actions show that market entry in this industry is not just about inventing a molecule. It also depends on patents, licensing, data quality, and compliance, which raises the cost and time burden for any new competitor.\u003c\/p\u003e\n\n\u003cp\u003eBrand and market access are major moats. Biktarvy held \u003cstrong\u003e70.0%\u003c\/strong\u003e of the U.S. HIV market on 2024-09-30, and that level of share reflects years of physician familiarity, insurer coverage, and reliable supply. HIV sales reached \u003cstrong\u003e$19.6 billion\u003c\/strong\u003e in 2024, while total revenue was \u003cstrong\u003e$28.8 billion\u003c\/strong\u003e, so any entrant trying to take share has to displace a very large installed base. Gilead Sciences, Inc. also gave 2025 product-sales guidance of \u003cstrong\u003e$28.2 billion to $28.6 billion\u003c\/strong\u003e and posted \u003cstrong\u003e$7.6 billion\u003c\/strong\u003e in 2024-Q4 revenue, which signals ongoing strength with payers, distributors, and health systems. The \u003cstrong\u003e$4.3 billion\u003c\/strong\u003e CymaBay acquisition and \u003cstrong\u003e$320 million\u003c\/strong\u003e Janssen royalty buyout show that Gilead Sciences, Inc. can buy assets and simplify its position, while a newcomer would have to build that platform from zero.\u003c\/p\u003e\n\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eHigh share means high switching friction for doctors and payers.\u003c\/li\u003e\n \u003cli\u003eLarge revenue gives Gilead Sciences, Inc. more room to fund discounts, trials, and launches.\u003c\/li\u003e\n \u003cli\u003eAcquisitions let the company add capabilities faster than organic start-ups can.\u003c\/li\u003e\n \u003cli\u003eEstablished distribution makes it harder for a new drug to win shelf space and formulary access.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003ePipeline depth raises the entry bar even more. Gilead Sciences, Inc. is not dependent on one asset, because PURPOSE 2, ASCENT-04, and BIC\/LEN all delivered major Phase 3 milestones across HIV, oncology, and prevention between 2024 and 2025. Yeztugo launched on 2026-02-25, Livdelzi was approved in 2024, and Veklury still delivered about \u003cstrong\u003e$1.8 billion\u003c\/strong\u003e in 2024 revenue. A new entrant would need to clear different trial designs, reimbursement rules, and patient-access requirements across at least \u003cstrong\u003e120\u003c\/strong\u003e countries. Gilead Sciences, Inc. also tied this pipeline to a \u003cstrong\u003e$32.0 billion\u003c\/strong\u003e capital plan through 2030 and a \u003cstrong\u003e182,000 sq ft\u003c\/strong\u003e Foster City development center, which lowers its own development risk and raises the minimum scale a rival must reach to matter.\u003c\/p\u003e\n\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eMultiple late-stage programs reduce dependence on a single product.\u003c\/li\u003e\n \u003cli\u003eDifferent disease areas require different clinical proof, which slows imitation.\u003c\/li\u003e\n \u003cli\u003eGlobal access adds pricing and reimbursement complexity.\u003c\/li\u003e\n \u003cli\u003eLarge R\u0026amp;D facilities shorten development cycles for the incumbent, not the entrant.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003eCompliance and manufacturing are the final barrier. New entrants would have to absorb the same legal and operational burden that Gilead Sciences, Inc. has already paid for, including the \u003cstrong\u003e$202.0 million\u003c\/strong\u003e civil fraud settlement in 2025 and the five-year PrEP patent settlement with DOJ and HHS. They would also need to replicate more than \u003cstrong\u003e17,000\u003c\/strong\u003e employees, plus operational standards such as \u003cstrong\u003e100%\u003c\/strong\u003e renewable electricity and zero-waste-to-landfill practices at Foster City. Gilead Sciences, Inc.'s \u003cstrong\u003e$3.5 billion\u003c\/strong\u003e debt issuance in 2024-Q4 and \u003cstrong\u003e$10.0 billion\u003c\/strong\u003e year-end liquidity show the financing needed to keep manufacturing, clinical work, and regulatory defense running. Its \u003cstrong\u003e$28.8 billion\u003c\/strong\u003e in 2024 revenue and \u003cstrong\u003e$1.75 billion\u003c\/strong\u003e Trodelvy impairment also show that even a large incumbent can absorb expensive setbacks, which makes the hurdle much steeper for a smaller new firm.\u003c\/p\u003e","brand":"dcf.fm","offers":[{"title":"Default Title","offer_id":44600312758421,"sku":"gild-porters-five-forces-analysis","price":7.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0630\/5189\/0837\/files\/gild-porters-five-forces-analysis.png?v=1740177778","url":"https:\/\/dcf-model.com\/es\/products\/gild-porters-five-forces-analysis","provider":"AI-Powered Discounted Cash Flow Model Templates","version":"1.0","type":"link"}